Delivery Order SPE2DB24D2018-SPE2DB25FWUH2

Award Date 4/28/25
Potential Completion Date 4/29/25
Potential Value $4.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,434.34, is for the supply of Mounjaro 10 mg/0.5 ml pens, a medication used to treat diabetes. The contract is a firm fixed-price delivery order with an ultimate completion date of April 21, 2025. The contract is not designated as a set-aside and was open to full and open competition....
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,530.64 contract is for the supply of Mounjaro 5 mg/0.5 ml pens, a diabetes medication. The order has an ultimate completion date of April 16, 2025. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,448.81, is for the provision of Mounjaro 7.5 mg/0.5 ml pens, a diabetes treatment medication. The contract is a firm fixed-price delivery order with an ultimate completion date of April 22, 2025. AmerisourceBergen Drug Corp is the prime contractor, and there is no set-aside designation for this award. The contract is part...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,465.65 firm fixed-price contract is for the delivery of Mounjaro 7.5 mg/0.5 ml pens, a medication used to treat diabetes. The contract has an ultimate completion date of February 26, 2025 and is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Mounjaro 10 mg/0.5 ml pens, a diabetes treatment medication. The contract has a firm fixed price, with a ceiling value of $2,708.45, and a period of performance ending on April 18, 2025. This contract is not set aside and is open to competition. AmerisourceBergen Drug Corp holds a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Mounjaro 15 mg/0.5 ml pens, a diabetes treatment medication. The total ceiling value of the contract is $1,904.63, and it has a period of performance through April 29, 2025. The contract is a firm-fixed-price, non-set-aside award, indicating open competition. AmerisourceBergen Drug Corp holds a significant...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,678.18, is for the delivery of Mounjaro 7.5 mg/0.5 ml pens, a medication used to treat diabetes. The order is a firm-fixed-price delivery order with an ultimate completion date of April 30, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,897.62, is for the supply of Mounjaro 7.5 mg/0.5 ml pens, a diabetes medication. The contract has an ultimate completion date of April 28, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $10,729.41, is for the provision of Mounjaro 5 mg/0.5 ml pens, a medication used to treat diabetes. The contract is a firm fixed-price delivery order, with a performance period extending through May 2025. AmerisourceBergen Drug Corp is the prime contractor, and there is no set-aside designation, indicating the contract was...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $29,832.44, is for the delivery of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a medication used to treat diabetes. The contract is a firm fixed-price delivery order, with an ultimate completion date of April 29, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
  • SPE2DB24D2018
    Indefinite Delivery Contract
  • SPE2DB24D2018-SPE2DB25FWUH2
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $4,874.91 firm-fixed-price contract is for the supply of Mounjaro 5 mg/0.5 ml pens, a diabetes medication. The contract has an ultimate completion date of April 29, 2025. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle for various government agencies, including the Defense Health Agency and U.S. Coast Guard, through December 2026. The contract is not set aside and is open to full and open competition.

Generated 8/3/25, 1:26 AM